Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Acquired resistance to endocrine treatments is associated with tumor-specific molecular changes in patient-derived luminal breast cancer xenografts.
Cottu P, Bièche I, Assayag F, El Botty R, Chateau-Joubert S, Thuleau A, Bagarre T, Albaud B, Rapinat A, Gentien D, de la Grange P, Sibut V, Vacher S, Hatem R, Servely JL, Fontaine JJ, Decaudin D, Pierga JY, Roman-Roman S, Marangoni E. Cottu P, et al. Among authors: assayag f. Clin Cancer Res. 2014 Aug 15;20(16):4314-25. doi: 10.1158/1078-0432.CCR-13-3230. Epub 2014 Jun 19. Clin Cancer Res. 2014. PMID: 24947930
A new model of patient tumor-derived breast cancer xenografts for preclinical assays.
Marangoni E, Vincent-Salomon A, Auger N, Degeorges A, Assayag F, de Cremoux P, de Plater L, Guyader C, De Pinieux G, Judde JG, Rebucci M, Tran-Perennou C, Sastre-Garau X, Sigal-Zafrani B, Delattre O, Diéras V, Poupon MF. Marangoni E, et al. Among authors: assayag f. Clin Cancer Res. 2007 Jul 1;13(13):3989-98. doi: 10.1158/1078-0432.CCR-07-0078. Clin Cancer Res. 2007. PMID: 17606733
Clinical relevance of human cancer xenografts as a tool for preclinical assessment: example of in-vivo evaluation of topotecan-based chemotherapy in a panel of human small-cell lung cancer xenografts.
Némati F, Daniel C, Arvelo F, Legrier ME, Froget B, Livartowski A, Assayag F, Bourgeois Y, Poupon MF, Decaudin D. Némati F, et al. Among authors: assayag f. Anticancer Drugs. 2010 Jan;21(1):25-32. doi: 10.1097/CAD.0b013e3283300a29. Anticancer Drugs. 2010. PMID: 19823076
Establishment and characterisation of a new breast cancer xenograft obtained from a woman carrying a germline BRCA2 mutation.
de Plater L, Laugé A, Guyader C, Poupon MF, Assayag F, de Cremoux P, Vincent-Salomon A, Stoppa-Lyonnet D, Sigal-Zafrani B, Fontaine JJ, Brough R, Lord CJ, Ashworth A, Cottu P, Decaudin D, Marangoni E. de Plater L, et al. Among authors: assayag f. Br J Cancer. 2010 Oct 12;103(8):1192-200. doi: 10.1038/sj.bjc.6605900. Epub 2010 Sep 28. Br J Cancer. 2010. PMID: 20877358 Free PMC article.
Modeling of response to endocrine therapy in a panel of human luminal breast cancer xenografts.
Cottu P, Marangoni E, Assayag F, de Cremoux P, Vincent-Salomon A, Guyader Ch, de Plater L, Elbaz C, Karboul N, Fontaine JJ, Chateau-Joubert S, Boudou-Rouquette P, Alran S, Dangles-Marie V, Gentien D, Poupon MF, Decaudin D. Cottu P, et al. Among authors: assayag f. Breast Cancer Res Treat. 2012 Jun;133(2):595-606. doi: 10.1007/s10549-011-1815-5. Epub 2011 Oct 16. Breast Cancer Res Treat. 2012. PMID: 22002565
Molecular profiling of patient-derived breast cancer xenografts.
Reyal F, Guyader C, Decraene C, Lucchesi C, Auger N, Assayag F, De Plater L, Gentien D, Poupon MF, Cottu P, De Cremoux P, Gestraud P, Vincent-Salomon A, Fontaine JJ, Roman-Roman S, Delattre O, Decaudin D, Marangoni E. Reyal F, et al. Among authors: assayag f. Breast Cancer Res. 2012 Jan 16;14(1):R11. doi: 10.1186/bcr3095. Breast Cancer Res. 2012. PMID: 22247967 Free PMC article.
Pyrophosphorolysis-activated polymerization detects circulating tumor DNA in metastatic uveal melanoma.
Madic J, Piperno-Neumann S, Servois V, Rampanou A, Milder M, Trouiller B, Gentien D, Saada S, Assayag F, Thuleau A, Nemati F, Decaudin D, Bidard FC, Desjardins L, Mariani P, Lantz O, Stern MH. Madic J, et al. Among authors: assayag f. Clin Cancer Res. 2012 Jul 15;18(14):3934-41. doi: 10.1158/1078-0432.CCR-12-0309. Epub 2012 May 29. Clin Cancer Res. 2012. PMID: 22645051
Inhibiting aurora kinases reduces tumor growth and suppresses tumor recurrence after chemotherapy in patient-derived triple-negative breast cancer xenografts.
Romanelli A, Clark A, Assayag F, Chateau-Joubert S, Poupon MF, Servely JL, Fontaine JJ, Liu X, Spooner E, Goodstal S, de Cremoux P, Bièche I, Decaudin D, Marangoni E. Romanelli A, et al. Among authors: assayag f. Mol Cancer Ther. 2012 Dec;11(12):2693-703. doi: 10.1158/1535-7163.MCT-12-0441-T. Epub 2012 Sep 25. Mol Cancer Ther. 2012. PMID: 23012245
32 results